|Podcasts|January 19, 2011
Build A Drug's Value in Early
Advertisement
Build a Drug's Value in Early
Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
2
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
3
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
4
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
5